Your browser doesn't support javascript.
loading
The landscape of mRNA nanomedicine.
Huang, Xiangang; Kong, Na; Zhang, Xingcai; Cao, Yihai; Langer, Robert; Tao, Wei.
Afiliação
  • Huang X; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Kong N; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Zhang X; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Cao Y; School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA.
  • Langer R; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. yihai.cao@ki.se.
  • Tao W; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
Nat Med ; 28(11): 2273-2287, 2022 11.
Article em En | MEDLINE | ID: mdl-36357682
ABSTRACT
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanomedicina / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanomedicina / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article